LONDON, UK / ACCESSWIRE / January 08, 2018 / Active-Investors.com has just released a free research report on Chimerix, Inc. (NASDAQ: CMRX). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CMRX as the Company's latest news hit the wire. On January 05, 2018, the biopharmaceutical Company announced initiation of AdAPT study evaluating brincidofovir's (CMX001) antiviral effect in pediatric stem cell transplant recipients facing confirmed life-threatening adenovirus (AdV) infection. Register today and get access to over 1000 Free Research Reports by joining our site below:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Chimerix most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Progression of Intravenous BCV to Phase-2 Studies in Virally Infected Transplant Recipients
The Company also reported successful administration of intravenous (IV) BCV without dose-limiting gastrointestinal events, supporting the advancement to Phase-2 studies of IV BCV in virally infected transplant recipients. Proposals for the Phase-2 studies of IV BCV in virally-infected patients are currently being reviewed by regulators in Europe, and are likely to provide data by the end of 2018. Chimerix also announced that its new molecule, CMX521, is the first direct-acting antiviral for norovirus to progress to clinical-stage development. The Phase-1 study will evaluate the pharmacokinetics, safety and tolerability of CMX521 in up to 50 adult subjects.
AdAPT Study of Oral Brincidofovir in Adenovirus
AdAPT (Adenovirus After Pediatric Transplantation) study will enroll 141 pediatric allogeneic hematopoietic stem cell transplant (HCT) recipients with confirmed adenovirus infection. Patients will be randomized to receive short-course oral BCV or local standard-of-care (SOC) treatment at around 30 sites in Europe and the United States. The primary endpoint is a comparison of average adenovirus virus burden over 16 weeks between oral BCV and SOC treatment. The study will also evaluate the correlation of AdV burden with clinical outcomes including survival. Enrollment is estimated to complete in 2019. Positive data from AdAPT is expected to provide the basis for a European marketing approval.
Completion of MAD Study of IV BCV in Healthy Subjects
Chimerix declared the successful completion of the multiple ascending dose (MAD) study of IV BCV in healthy subjects. The study evaluated the safety, tolerability and pharmacokinetics of IV BCV 10 mg given twice weekly and IV BCV 20 mg given once weekly in healthy subjects for two to four weeks. IV BCV was well-tolerated at all dose levels, with no dose-limiting clinical adverse events. Proposals for studies of IV BCV in virally-infected patients have progressed to regulatory review in Europe and are expected to provide data in the second half of the year.
Preliminary Data from Phase-1 Dose Escalation Study of Intravenous Brincidofovir Announced Last Year
On January 06, 2017, Chimerix announced preliminary data from Phase-1 study to investigate the safety, tolerability and plasma/intracellular concentration of intravenous brincidofovir following single escalating doses in healthy adult subjects. In the ongoing study, IV administration of BCV demonstrated a favorable tolerability profile. No drug related adverse events were identified. Notably, gastrointestinal side effects were absent.
About Brincidofovir (CMX001)
Brincidofovir, Chimerix's lead product candidate, is a nucleotide analog that has shown broad-spectrum antiviral activity against the most important DNA viruses that affect humans, including adenovirus, the virus that causes smallpox (Variola) and cytomegalovirus (CMV). Brincidofovir has a high barrier to resistance, no myelosuppression and low risk of nephrotoxicity.
About Chimerix, Inc.
Founded in 2000 and based in Durham, North Carolina, Chimerix is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines that improve outcomes for immunocompromised patients. The Company's proprietary lipid conjugate technology has produced brincidofovir; CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates.
Stock Performance Snapshot
January 05, 2018 - At Friday's closing bell, Chimerix's stock advanced 2.83%, ending the trading session at $5.09.
Volume traded for the day: 308.11 thousand shares.
Stock performance in the last month – up 14.38%; past twelve-month period – up 1.19%; and year-to-date - up 9.94%
After last Friday's close, Chimerix's market cap was at $242.95 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.9% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.